Chemomab Therapeutics (CMMB) is scheduled to report Q2 earnings on August 13, 2026. Analysts estimate EPS of $-0.08 and quarterly revenue of N/A.
In the most recent quarter (Q1), Chemomab Therapeutics reported EPS of $-0.24, missing estimates of $-0.08 by 2.00%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.
Chemomab Therapeutics has missed EPS estimates in 3 consecutive quarters.
Over the last 4 quarters, Chemomab Therapeutics has averaged an EPS surprise of 1.30% and a revenue surprise of 0.00%.
Analyze the earnings history of Chemomab Therapeutics using advanced sorting and filters.
The chart below shows Chemomab Therapeutics's reported EPS compared to analyst estimates over recent quarters.
The chart below shows Chemomab Therapeutics's reported revenue compared to analyst estimates over recent quarters.
Chemomab Therapeutics (CMMB) is scheduled to report earnings on August 13, 2026. The last reported earnings were for reported on May 14, 2026 for Q1.
The Actual EPS was $-0.24, which missed the estimate of $-0.08.
The Actual Revenue was $0.00, which hit the estimate of $0.00.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | 2026-05-14 | $-0.24 | $-0.08 | -200.0 % |
| Q4 | 2026-03-19 | $-0.24 | $-0.10 | -140.0 % |
| Q3 | 2025-11-20 | $-0.28 | $-0.10 | -180.0 % |
| Q2 | 2025-08-14 | $-0.36 | $-0.36 | 0.00 % |